Prevalence of Coronavirus Disease 2019 Infection and Outcomes Among Symptomatic Healthcare Workers in Seattle, Washington.
COVID-19
employee health
healthcare workers
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
17 12 2020
17 12 2020
Historique:
received:
13
05
2020
accepted:
11
06
2020
pubmed:
18
6
2020
medline:
26
3
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
Healthcare workers (HCWs) who serve on the front lines of the coronavirus disease 2019 (COVID-19) pandemic have been at increased risk for infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in some settings. Healthcare-acquired infection has been reported in similar epidemics, but there are limited data on the prevalence of COVID-19 among HCWs and their associated clinical outcomes in the United States. We established 2 high-throughput employee testing centers in Seattle, Washington, with drive-through and walk-through options for symptomatic employees in the University of Washington Medicine system and its affiliated organizations. Using data from these testing centers, we report the prevalence of SARS-CoV-2 infection among symptomatic employees and describe the clinical characteristics and outcomes among employees with COVID-19. Between 12 March 2020 and 23 April 2020, 3477 symptomatic employees were tested for COVID-19 at 2 employee testing centers; 185 (5.3%) employees tested positive for COVID-19. The prevalence of SARS-CoV-2 was similar when comparing frontline HCWs (5.2%) with nonfrontline staff (5.5%). Among 174 positive employees reached for follow-up at least 14 days after diagnosis, 6 reported COVID-related hospitalization; all recovered. During the study period, we observed that the prevalence of positive SARS-CoV-2 tests among symptomatic HCWs was comparable to that of symptomatic nonfrontline staff. Reliable and rapid access to testing for employees is essential to preserve the health, safety, and availability of the healthcare workforce during this pandemic and to facilitate the rapid return of SARS-CoV-2-negative employees to work.
Sections du résumé
BACKGROUND
Healthcare workers (HCWs) who serve on the front lines of the coronavirus disease 2019 (COVID-19) pandemic have been at increased risk for infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in some settings. Healthcare-acquired infection has been reported in similar epidemics, but there are limited data on the prevalence of COVID-19 among HCWs and their associated clinical outcomes in the United States.
METHODS
We established 2 high-throughput employee testing centers in Seattle, Washington, with drive-through and walk-through options for symptomatic employees in the University of Washington Medicine system and its affiliated organizations. Using data from these testing centers, we report the prevalence of SARS-CoV-2 infection among symptomatic employees and describe the clinical characteristics and outcomes among employees with COVID-19.
RESULTS
Between 12 March 2020 and 23 April 2020, 3477 symptomatic employees were tested for COVID-19 at 2 employee testing centers; 185 (5.3%) employees tested positive for COVID-19. The prevalence of SARS-CoV-2 was similar when comparing frontline HCWs (5.2%) with nonfrontline staff (5.5%). Among 174 positive employees reached for follow-up at least 14 days after diagnosis, 6 reported COVID-related hospitalization; all recovered.
CONCLUSIONS
During the study period, we observed that the prevalence of positive SARS-CoV-2 tests among symptomatic HCWs was comparable to that of symptomatic nonfrontline staff. Reliable and rapid access to testing for employees is essential to preserve the health, safety, and availability of the healthcare workforce during this pandemic and to facilitate the rapid return of SARS-CoV-2-negative employees to work.
Identifiants
pubmed: 32548613
pii: 5858272
doi: 10.1093/cid/ciaa761
pmc: PMC7337651
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2702-2707Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007742
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2020 Nov 19;71(16):2218-2221
pubmed: 32179890
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
J Hosp Infect. 2011 Apr;77(4):332-7
pubmed: 21316802
JAMA. 2020 Jun 2;323(21):2133-2134
pubmed: 32259193
J Hosp Infect. 2020 May;105(1):100-101
pubmed: 32147406
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
JAMA. 2020 Apr 21;323(15):1439-1440
pubmed: 32163102
JAMA. 2020 May 26;323(20):2087-2089
pubmed: 32301962
Clin Infect Dis. 2020 Jul 28;71(15):858-860
pubmed: 32166318
BMJ. 2020 Mar 26;368:m1254
pubmed: 32217525
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-481
pubmed: 32298247
N Engl J Med. 2020 Jun 4;382(23):2267-2268
pubmed: 32294342
Infect Control Hosp Epidemiol. 2020 Jun;41(6):745-746
pubmed: 32131906
Ann Intern Med. 2020 Jul 21;173(2):120-136
pubmed: 32369541
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350048